INTRODUCTION
Curcumin (CUM) presents antineoplastic properties and its incorporation into cationic solid lipid nanoparticles (CSLN) is convenient in order to compartmentalize and delivery this drug to melanoma cells, can be used in melanoma prevention and treatment (1).
METHODS
Formulations preparation
All formulations were produced with Poloxamer 407 (3.2%), cetrimonium bromide (0.7%), water (91.1%), and solid lipids (5%), which were varied obtained F1 composed by stearic acid, F3 composed by Compritol 888 ATO and F2 composed by a blend of both lipids. The ingredients were mixtures and sonicated for 20 minutes at 12-17 W. It were performed determinations of mean hydrodynamic diameter (Dnm), polydispersity index (PdI) and zeta potential (ZP) of each formulation.
Cell viability assay of HaCaT and B16-F10 cells by MTT technique
Healthy keratinocytes cells (HaCaT) and tumorigenic melanocytic cells (B16-F10) were treated with formulations, CUM-free, Doxorubicin solution (PC) and culture medium (NC). After the treatments, the cell viability was evaluated using the MTT technique.
RESULTS AND DISCUSSION
There was obtained systems with Dnm of 218-238 nm, PdI of 0,185–0,350 and ZP of 25,6–30,1 mV.
Viability cells tests showed that the systems developed are more toxic to B16-F10 than HaCat and the incorporation of CUM in CSLNs increase the toxicity of this drug to melanoma cells (B16F10), because the positive charge presented by these systems may promote drug targeting to melanoma cells, that have a high density of negative charge due to high exposure of phosphatidylserine on the surface of cell (2), showing that the CUM-loaded-CSLN are promising for the treatment of melanoma (Figure 1).
(Attach figure 1)
Figure 1. Cell viability assay of HaCaT (a) and B16F10 (b), after exposed to treatments.
REFERENCES
1. Sharma R.A. et al. Eur J Cancer, 41, 1955–1968, 2005.
2. Sakamoto, J. H. et al., Pharmacol. Res., 62, 57–89, 2010.
ACKNOWLEDGEMENTS
This work was financially supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP).
Targeted drug delivery and Nanocarriers , Nanomedecine for cancer diagnosis & therapy
